Understanding the Breakthrough in Hereditary Angioedema Treatment through CRISPR-Cas9 Gene Editing

Hereditary angioedema (HAE) is a rare genetic disorder marked by sudden, severe swelling attacks.. These attacks can occur in various parts of the body, including the skin, gastrointestinal tract, and airways, leading to potentially life-threatening complications. A key gene implicated in HAE's onset is KLKB1, which is responsible for producing the enzyme kallikrein B1. Plasma kallikrein plays a crucial role in the swelling process associated with HAE. Therefore, targeting the KLKB1 gene offers a promising therapeutic approach by reducing the activity of this enzyme.

The study “CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema,” (1) featured in the New England Journal of Medicine (February 1, 2024), explores this concept. It introduces an innovative CRISPR-Cas9-based gene therapy, named NTLA-2002, to target the KLKB1 gene.

The Study and Its Findings

In a Phase 1 trial, patients with hereditary angioedema received varying doses of NTLA-2002. The results were promising:

• Safety and Tolerability: NTLA-2002 was found to be safe, with no severe adverse events, serious adverse events, or clinically significant laboratory findings. The most common side effects were mild, such as infusion-related reactions and fatigue (1).

• Effectiveness in Reducing Kallikrein Levels: There was a dose-dependent reduction in total plasma kallikrein levels, indicating successful gene editing. The reductions were −67% in the 25mg group, −84% in the 50mg group, and −95% in the 75mg group (1).

• Reduction in Angioedema Attacks: The frequency of angioedema attacks decreased significantly, with a −91% reduction in the 25mg group, −97% in the 50mg group, and −80% in the 75mg group (1).
  

Summary

This study demonstrates that a single dose of NTLA-2002 is safe and can lead to robust, dose-dependent, and durable reductions in total plasma kallikrein levels. More importantly, it significantly reduces the frequency of angioedema attacks, which could dramatically improve the quality of life for patients with HAE. These results mark a major advancement in HAE's genetic therapies.

For more detailed information, and a complete understanding, readers are encouraged to refer to the full text of the study. The study was funded by Intellia Therapeutics - ClinicalTrials.gov number, NCT05120830 (2).

References and further reading

1. CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema

2. NTLA-2002 in Adults With Hereditary Angioedema (HAE) (NTLA-2002)